Clinical Trial

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2020-01-15; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2023-11-21
Trial Details
NCT Number NCT04234048
Lead Sponsor SciTech Development, Inc.
Conditions T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma +3 more
Enrollment 46 participants
Start Date 2023-12-18
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-22